AtriCure, Inc. (ATRC): Price and Financial Metrics

AtriCure, Inc. (ATRC): $73.13

0.82 (+1.13%)

POWR Rating

Component Grades














  • ATRC scores best on the Stability dimension, with a Stability rank ahead of 54.45% of US stocks.
  • ATRC's strongest trending metric is Stability; it's been moving up over the last 52 weeks.
  • ATRC ranks lowest in Value; there it ranks in the 21st percentile.

ATRC Stock Summary

  • For ATRC, its debt to operating expenses ratio is greater than that reported by merely 23.87% of US equities we're observing.
  • With a price/sales ratio of 13.65, AtriCure Inc has a higher such ratio than 86.49% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.76 for AtriCure Inc; that's greater than it is for 32.41% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AtriCure Inc are REFR, XENT, REKR, BIOL, and TWOU.
  • Visit ATRC's SEC page to see the company's official filings. To visit the company's web site, go to

ATRC Valuation Summary

  • ATRC's price/sales ratio is 13.9; this is 22.47% higher than that of the median Healthcare stock.
  • Over the past 196 months, ATRC's price/sales ratio has gone down 2.2.
  • Over the past 196 months, ATRC's price/sales ratio has gone down 2.2.

Below are key valuation metrics over time for ATRC.

Stock Date P/S P/B P/E EV/EBIT
ATRC 2021-08-31 13.9 8.8 -59.6 -65.5
ATRC 2021-08-30 13.9 8.8 -59.8 -65.7
ATRC 2021-08-27 14.1 8.9 -60.3 -66.3
ATRC 2021-08-26 13.7 8.6 -58.7 -64.6
ATRC 2021-08-25 14.0 8.8 -60.0 -65.9
ATRC 2021-08-24 14.3 9.0 -61.5 -67.5

ATRC Growth Metrics

  • Its 2 year net income to common stockholders growth rate is now at -71.24%.
  • Its 4 year cash and equivalents growth rate is now at 4.81%.
  • The year over year net income to common stockholders growth rate now stands at -5.87%.
ATRC's revenue has moved up $41,503,000 over the prior 30 months.

The table below shows ATRC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 243.133 -6.083 -56.679
2021-03-31 212.581 -13.098 -48.664
2020-12-31 206.531 -19.869 -48.155
2020-09-30 210.127 -27.352 -45.689
2020-06-30 211.984 -33.754 -50.102
2020-03-31 230.066 -18.46 -45.967

ATRC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ATRC has a Quality Grade of C, ranking ahead of 31.67% of graded US stocks.
  • ATRC's asset turnover comes in at 0.344 -- ranking 124th of 186 Medical Equipment stocks.
  • INGN, ABMD, and BSX are the stocks whose asset turnover ratios are most correlated with ATRC.

The table below shows ATRC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.344 0.746 -0.169
2021-03-31 0.301 0.729 -0.142
2020-12-31 0.311 0.723 -0.152
2020-09-30 0.337 0.722 -0.163
2020-06-30 0.361 0.722 -0.213
2020-03-31 0.463 0.736 -0.227

ATRC Price Target

For more insight on analysts targets of ATRC, see our ATRC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $96.71 Average Broker Recommendation 1.31 (Strong Buy)

ATRC Stock Price Chart Interactive Chart >

Price chart for ATRC

ATRC Price/Volume Stats

Current price $73.13 52-week high $85.50
Prev. close $72.31 52-week low $34.04
Day low $70.87 Volume 97,000
Day high $73.71 Avg. volume 310,902
50-day MA $73.06 Dividend yield N/A
200-day MA $70.88 Market Cap 3.36B

AtriCure, Inc. (ATRC) Company Bio

Atricure provides atrial fibrillation solutions worldwide. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The company was founded in 2000 and is based in West Chester, Ohio.

ATRC Latest News Stream

Event/Time News Detail
Loading, please wait...

ATRC Latest Social Stream

Loading social stream, please wait...

View Full ATRC Social Stream

Latest ATRC News From Around the Web

Below are the latest news stories about AtriCure Inc that investors may wish to consider to help them evaluate ATRC as an investment opportunity.

Thoracic Surgery Market Growth, Trends, COVID-19 Impact, and Forecasts (2021 2027)| Boston Scientific, Medtronic, Abbott, AtriCure, BioVentrix

The latest Thoracic Surgery market study offers an all-inclusive analysis of the major strategies, corporate models, and market shares of the most noticeable players in this market. The study offers a thorough analysis of the key persuading factors, market figures in terms of revenues, segmental data, regional data, and country-wise data. Request a sample on []

Jumbo News | October 13, 2021

AtriCure to Announce Third Quarter 2021 Financial Results

MASON, Ohio, October 05, 2021--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021.

Yahoo | October 5, 2021

New Study from StrategyR Highlights a $80.1 Million Global Market for Tipper Trucks by 2026

SAN FRANCISCO , Sept. 15, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Tipper Trucks - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE Edition: 9; Released: April 2021 Executive Pool: 422 Companies: 43 - Players covered include Abbott Vascular; Abiomed, Inc.; AtriCure, Inc.; BEML Ltd.; Biosensors International Group Ltd.; Biotronik SE & Co. KG; BioVentrix, Inc.; Caterpillar, Inc.; Hitachi Construction Machinery Co., Ltd.; Komatsu Ltd.; OJSC Belaz and Others. Coverage: All major geographies and key segments Segments: Segment (Tipper Truc...

Benzinga | September 15, 2021

Cryoablation Devices Market to Witness Growth Acceleration by Top Key Players Like Smith & Nephew, Olympus, St. Jude, Boston, Conmed, Galil Medical, Atricure, Angiodynamics

Cryoablation Devices Market poised to witness significant growth owing to its ability to treat various diseased conditions in humans and animals. Availability of different products with customized probes for cryoablation will help boost this market over the forecast period. Other

OpenPR | September 10, 2021

Soft Tissue Dissectors Market to See Incredible Growth During 2021 2028 | Cadence Inc., AtriCure, Inc., Accurate Surgical & Scientific Instruments Corp, Ethicon US, LLC., Medtronic PLC

Soft tissues are the supporting, connective tissues that surround organs of the human body. The damage to soft tissues needs to be handled with intense care. Soft tissue dissection surgeries are frequently performed across the world. Soft tissue dissection is

OpenPR | September 2, 2021

Read More 'ATRC' Stories Here

ATRC Price Returns

1-mo -1.64%
3-mo -8.78%
6-mo 10.80%
1-year 92.65%
3-year 155.07%
5-year 312.00%
YTD 31.36%
2020 71.24%
2019 6.24%
2018 67.76%
2017 -6.80%
2016 -12.79%

Continue Researching ATRC

Here are a few links from around the web to help you further your research on AtriCure Inc's stock as an investment opportunity:

AtriCure Inc (ATRC) Stock Price | Nasdaq
AtriCure Inc (ATRC) Stock Quote, History and News - Yahoo Finance
AtriCure Inc (ATRC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8724 seconds.